AMP activated protein kinase (AMPK) regulates the coordination of anabolic and catabolic processes and is an attractive therapeutic target for T2DM, obesity and metabolic syndrome. Here, PRKAA2 is linked to obesity due to melanocortin 4 receptor deficiency.